Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia: clinical safety, efficacy, and correlative analysis.

Front Immunol · 2025 · PMC12738368 · PMID 41459484

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Moreover, among these patients who achieved a CRc, MRD-negative patients showed a trend of increased OS and PFS compared to MRD-positive patients, albeit with non-significant statistical differences between the groups (6-month OS, MRD– vs.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.